NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality

Stupp R, et al.：Eur J Cancer. 2012 Sep;48（14）:2192-202. doi: 10.1016/j.ejca.2012.04.011.

Clinical Practice Experience With Novo TTF-100A™System for Glioblastoma: The PatientRegistry Dataset （PRiDe）

Mrugala MM, et al.: Semin Oncol. 2014 Oct;41 Suppl 6:S4-S13. doi: 10.1053/j.seminoncol.2014.09.010.

Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma

Lacouture ME, et al.: Front Oncol. 2020 Jul 28;10:1045. doi: 10.3389/fonc.2020.01045. eCollection 2020.

Global post-marketing safety surveillance of Tumor Treating Fields（TTFields） in patients with high-grade glioma in clinical practice

Shi W, et al.: J Neurooncol. 2020 Jul;148（3）:489-500. doi: 10.1007/s11060-020-03540-6. Epub 2020 Jun 13.